Test−Negative 3 vs 2 Dose Non−Matched Severe Disease VE

Design	Control	Start Quarter	Adjusted	n	VE	95% CI
1	1	Q4 2021	N	63016	0.649	(0.559,0.721)
2	2	Q4 2021	N	57052	0.667	(0.581,0.735)
3	3	Q4 2021	N	6420	0.678	(0.576,0.779)
4	1	Q4 2021	Y	63016	0.707	(0.624,0.772)
5	2	Q4 2021	Y	57052	0.748	(0.669,0.809)
6	3	Q4 2021	Y	6420	0.752	(0.660,0.845)
7	1	Q1 2022	N	33879	0.670	(0.571,0.746)
8	2	Q1 2022	N	30305	0.687	(0.593,0.759)
9	3	Q1 2022	N	3870	0.701	(0.586,0.815)
10	1	Q1 2022	Y	33879	0.654	(0.536,0.742)
11	2	Q1 2022	Y	30305	0.713	(0.602,0.794)
12	3	Q1 2022	Y	3870	0.724	(0.610,0.837)
13	1	Q2 2022	N	11437	0.480	(0.109,0.697)
14	2	Q2 2022	N	10555	0.482	(0.111,0.698)
15	3	Q2 2022	N	1016	0.516	(0.133,0.899)
16	1	Q2 2022	Y	11437	0.466	(0.063,0.695)
17	2	Q2 2022	Y	10555	0.420	(−0.037,0.676)
18	3	Q2 2022	Y	1016	0.390	(−0.070,0.850)
19	1	Q3 2022	N	5480	0.390	(−0.514,0.754)
20	2	Q3 2022	N	5103	0.400	(−0.488,0.758)
21	3	Q3 2022	N	461	0.423	(−0.274,1.121)
22	1	Q3 2022	Y	5480	0.483	(−0.308,0.796)
23	2	Q3 2022	Y	5103	0.434	(−0.439,0.777)
24	3	Q3 2022	Y	461	0.568	(−0.078,1.215)